Market Overview

US Stock Futures Signal Lower Start On Wall Street

Related AAPL
AMOLED Panels for Apple Watch to be Supplied by LG Display
Fast Money Picks For September 17 - Apple Inc., EOG Resources Inc And More
Claman on Call: All Eyes on the Fed (Fox Business)
Related DGICA
Donegal Group Inc. CEO To Take Medical Leave Of Absence
Zacks Rank #1 Additions for Friday - Tale of the Tape

Pre-open movers

US stock futures fell in early pre-market trade, ahead of consumer credit data. Data on consumer credit for August will be released at 3:00 p.m. ET. Futures for the Dow Jones Industrial Average tumbled 131 points to 14,867.00, while the Standard & Poor's 500 index futures fell 16 points to 1,668.80. Futures for the Nasdaq 100 index dropped 27.75 points to 3,206.75.

A Peek Into Global Markets

European markets were lower today, with the Spanish Ibex Index falling 0.76%, London's FTSE 100 index dropping 0.82% and STOXX Europe 600 Index declining 0.88%. German DAX 30 index fell 1.13% and French CAC 40 Index declined 1.01%.

Asian markets ended lower today. Japan's Nikkei Stock Average fell 1.22%, Australia's ASX/S&P500 dropped 0.87%, Hong Kong's Hang Seng Index fell 0.71% and India's Sensex dropped 0.10%.

Broker Recommendation

Analysts at Jefferies upgraded Apple (NASDAQ: AAPL) from “hold” to “buy.” The target price for Apple has been raised from $425 to $600.

Apple's shares gained 0.62% to $486.02 in pre-market trading.

Breaking news

  • Gregory Mark Shepard announced today that he has sent a letter to the Boards of Directors of Donegal Group (NASDAQ: DGICA) and Donegal Mutual Insurance Company ("Donegal Mutual") proposing an amicable transaction. To read the full news, click here.
  • ArcelorMittal (NYSE: MT) and Sider, an Algerian state-owned company, signed a strategic agreement on Saturday 5 October that includes an investment plan of US$763m for the steel complex at Annaba and the mines in Ouenza and Boukhadra. To read the full news, click here.
  • Cell Therapeutics (NASDAQ: CTIC) today announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 clinical trial, known as the PERSIST-2 trial, evaluating pacritinib compared to best available therapy, including approved JAK2 inhibitors such as ruxolitinib, in patients with myelofibrosis whose platelet counts are <100,000/uL. To read the full news, click here.
  • Gemino Healthcare Finance today announced it has been acquired by Solar Senior Capital (NASDAQ: SUNS). To read the full news, click here.

Posted-In: Jefferies US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

 

Related Articles (AAPL + CTIC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters